Aspen launches novel ARV Combination: Set to further improve treatment options

 

Aspen Pharmacare, South Africa’s leading JSE-listed pharmaceutical company, is pleased to announce the launch of Emdolten®, a Dolutegravir-based triple combination anti-retroviral (ARV) treatment option.

Emdolten®, a once a day triple combination tablet therapy in the form of Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate, is positioned to become a preferred first line ARV and will be available in 50mg, 300mg/300mg dosage strengths.

Stavros Nicolaou, Aspen Senior Executive, Strategic Trade, said, “There has been significant excitement at a clinician, funder and patient level about the use of Dolutegravir, a second generation integrase inhibitor, which offers clinical and safety profile benefits. Emdolten® enhances Aspen’s HIV product offering in South Africa and has the potential to improve the lives of millions of South Africans presently on ARV treatment. As part of our ARV leadership, we were able to introduce the first Dolutegravir and Dolutegravir-containing combinations into the South African market over 18 months ago. This represents a further refinement of Dolutegravir-containing combinations.”

“Aspen pioneered the development and manufacture of generic ARVs in South Africa in the early 2000s, when our country was grappling with HIV denial and the potentially destructive consequences of an un-arrested HIV pandemic. Prior to this, ARV’s, which were then patent protected, were inaccessible to the majority of these patients.”

Aspen’s pioneering efforts resulted in the accelerated introduction of South Africa’s public ARV programme which has contributed to the successful treatment of hundreds of thousands of patients afflicted with HIV and AIDS.

“Since the launch of Aspen Stavudine, our first generic ARV in August 2003, we have continued to be an anchor supplier of ARVs to both the South African public and private sectors, a leadership position we have maintained through extensive manufacturing investment into the local economy and the introduction of an ongoing pipeline of ARV products. This has enabled Aspen to bring the latest ARV innovations to market, providing patients and healthcare professionals with the most advanced ARV treatment options for patients’ specific needs,” added Nicolaou.

 

About Aspen
Aspen is a leading global player in specialty, branded and generic pharmaceuticals with an extensive basket of products that provide treatment for a broad spectrum of acute and chronic conditions experienced through all stages of life.
With an acknowledged presence of nearly 2 decades in the pharmaceutical sector, Aspen remains committed to its core values of providing quality and effective healthcare solutions to millions of patients in more than 150 countries, with its core focus being in Regional Brands, Thrombosis, Anaesthetic, High Potency & Cytotoxic and Nutritionals categories.
Aspen has a strong presence in both emerging and developed countries. Its emerging market footprint includes Sub-Saharan Africa, Latin America, China, South East Asia, Eastern Europe and the Commonwealth of Independent States, comprising Russia and the former Soviet Republics. It is also a leading pharmaceutical company in developed countries including Australia and most notably in Western Europe.
Aspen operates with an established business presence in some 70 countries spanning 6 continents and employs more than 10 000 people. The Group operates 25 manufacturing facilities across 17 sites. Aspen holds international manufacturing approvals from some of the most stringent global regulatory agencies including the FDA, TGA and EMA. Aspen’s manufacturing capabilities are scalable to demand and cover a wide variety of product-types including injectables, oral solid dose, liquids, semi-solids, steriles, biologicals, APIs and infant nutritionals.
With a market capitalisation of nearly US$10 billion, Aspen is the largest pharmaceutical company listed on the JSE Limited (share code: APN) and ranks amongst the top 20 listed companies on this exchange. For more information visit: http://www.aspenpharma.com/
Wildcard SSL